IBS Primary Logo Blue.png
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
31 oct. 2024 08h30 HE | Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions has partnered with B2i Digital to execute an investor communications program.
IBS Primary Logo Blue.png
Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil
24 oct. 2024 08h30 HE | Intelligent Bio Solutions, Inc.
INBS announces one year of enhanced workplace safety with Mount Anvil following the integration of fingerprint drug testing.
IBS Primary Logo Blue.png
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution
09 oct. 2024 08h30 HE | Intelligent Bio Solutions, Inc.
INBS announces its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency.
IBS Primary Logo Blue.png
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
27 sept. 2024 08h30 HE | Intelligent Bio Solutions, Inc.
INBS successfully completes in-clinic testing proposed to the FDA earlier this year in its clinical study plan.
IBS Primary Logo Blue.png
Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission
05 sept. 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Primary Logo Blue.png
Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees
03 sept. 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leader in non-invasive drug testing technology, today announced significant...
IBS Primary Logo Blue.png
Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries
13 août 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as...
IBS Logo Primary.jpg
Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Accounts
09 juil. 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...